Georgetown University Medical Center, Washington, DC, USA.
Future Oncol. 2022 Aug;18(26):2865-2870. doi: 10.2217/fon-2022-0073. Epub 2022 Jul 25.
WHAT IS THIS STUDY ABOUT?: This plain language summary reports the findings of a recent review of fusion-positive tumors.
WHAT ARE FUSIONS?: A gene fusion occurs when two genes join to create a new gene. This rearrangement of DNA can change the processes within normal cells and lead to cancer. One of these gene fusions involves the gene. fusions have been reported in several types of cancers. These are known as fusion-positive cancers.
WHAT TREATMENTS ARE AVAILABLE FOR PEOPLE WITH FUSION-POSITIVE CANCER?: One drug that has been studied in people with fusion-positive cancer is called afatinib. People with several cancer types have received afatinib in clinical trials, and some people have responded to afatinib. Further studies are required to understand how effective afatinib and other treatments are for fusion-positive cancer.
这项研究是关于什么的？：本通俗易懂的摘要报告了最近对融合阳性肿瘤的一项综述的结果。
什么是融合？：当两个基因连接在一起形成一个新基因时，就会发生基因融合。这种 DNA 的重排可以改变正常细胞内的过程，导致癌症。其中一种基因融合涉及基因。已经在几种类型的癌症中报告了融合。这些被称为融合阳性癌症。
对于患有融合阳性癌症的人有哪些治疗方法？：一种在患有融合阳性癌症的人中进行研究的药物称为阿法替尼。几种癌症类型的患者在临床试验中接受了阿法替尼治疗，一些患者对阿法替尼有反应。需要进一步的研究来了解阿法替尼和其他治疗方法对融合阳性癌症的有效性。
